The phosphatidylinositol-3-kinase pathway is one of the most commonly mutated pathways in invasive breast carcinoma, with PIK3CA mutations in B25% of invasive carcinomas, and AKT1 mutations in up to 5%. Ductal carcinoma in situ, and benign papillomas harbor similar mutations. However, activating point mutations in breast columnar cell lesions have been infrequently studied. Twenty-three breast resection specimens containing columnar cell lesions were identified; 14 with associated invasive carcinoma or carcinoma in situ. DNA extracts were prepared from formalin-fixed paraffin-embedded tissue and screened for a panel of point mutations (321 mutations in 30 genes) using a multiplex PCR panel with mass-spectroscopy readout. PIK3CA mutations were identified in 13/24 columnar cell lesions (54%) and 3/8 invasive carcinomas (37%). The mutation status of columnar cell lesions and associated carcinoma was frequently discordant. Of the 14 cases, only 5 demonstrated the same genotype in matched samples of columnar cell lesions and carcinoma (4 wild type, 1 PIK3CA H1047R). Interestingly, five patients had mutations in columnar cell lesions with wild-type carcinoma; two patients had different point mutations in columnar cell lesions and carcinoma. Only three cases had wildtype columnar cell lesion and mutated carcinoma. The 50% PIK3CA mutation prevalence in columnar cell lesions is greater than reported in most studies of invasive breast cancer. Further, columnar cell lesions and carcinoma were frequently discordant for PIK3CA/AKT1 mutation status. These findings raise interesting questions about the role of PIK3CA/AKT pathway in breast carcinogenesis, and the biologic/precursor potential of columnar cell lesions. The phosphatidylinositol-3-kinase pathway is activated in numerous cancer types and is one of the most commonly mutated pathways in invasive breast carcinoma. Activating mutations in the phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) are present in B25% of invasive carcinomas, with mutations clustering in 'hotspots' in exon 9 (helical domain) and exon 20 (kinase domain).
1-10In addition, this pathway is activated by mutations in the plekstrin-homology domain of AKT1 in up to 5% of breast carcinomas, or by the loss of the phosphatase PTEN (phosphatase and tensin homolog) in nearly half of breast cancers.2,11 Several groups have demonstrated a similar frequency of mutations in breast carcinoma in situ, with paired invasive and in situ carcinoma from the same patient concordant for PIK3CA mutation status in 66-100% of tested cases.12-15 However, other breast proliferative or putative precursor lesions have been little studied. Li et al 13 found PIK3CA hotspot mutations in only 6% of 52 tested cases of Ductal Intraepithelial Neoplasia 1A-B lesions (DIN1A-B, atypical ductal hyperplasia and flat epithelial atypia, also known as columnar cell change with atypia). Our group previously identified PIK3CA/